Lori Pierce is a breast radiation oncologist and ASCO past president focused on equity in cancer care.
Lori Pierce is Professor of Radiation Oncology and Vice Provost at the University of Michigan, within the University of Michigan Rogel Cancer Center, a senior NRG Oncology investigator and past president of the American Society of Clinical Oncology (ASCO) for 2020 to 2021. A breast radiation oncologist, she studies radiotherapy in BRCA carriers and breast cancer outcomes by race, with a focus on health equity. Her papers include a comparison of breast conservation and mastectomy in BRCA1 and BRCA2 mutation carriers with operable breast cancer and ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. Her work spans triple-negative and HR-positive breast cancer and modern radiotherapy.
| Title | Journal | Year |
|---|---|---|
| Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy | Breast Cancer Research and Treatment | 2010 |
| Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer | Journal of Clinical Oncology | 2006 |
Shares Breast cancer research and treatment, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares Breast cancer research and treatment, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares Breast cancer research and treatment, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares University of Michigan Rogel Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Breast cancer research and treatment, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares Breast cancer research and treatment, HR-positive / HER2-negative breast cancer.
Shares BRCA1 / BRCA2 (HRD), IMRT / IGRT (modern external beam), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares American Society of Clinical Oncology (ASCO), BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.